

Professional organisation statement template

Thank you for agreeing to give us a statement on your organisation's view of the technology and the way it should be used in the NHS.

Healthcare professionals can provide a unique perspective on the technology within the context of current clinical practice which is not typically available from the published literature.

To help you in making your statement, we have provided a template. The questions are there as prompts to guide you. It is not essential that you answer all of them.

Please do not exceed the 8-page limit.

About you

Your name: [REDACTED]

Name of your organisation

Association of Upper GI Surgeons of GB and Ireland (AUGIS)

Are you (tick all that apply):

- a specialist in the treatment of people with the condition for which NICE is considering this technology? YES
- a specialist in the clinical evidence base that is to support the technology (e.g. involved in clinical trials for the technology)? NO
- an employee of a healthcare professional organisation that represents clinicians treating the condition for which NICE is considering the technology? If so, what is your position in the organisation where appropriate (e.g. policy officer, trustee, member etc.)?
- other? (please specify) YES - President of AUGIS

What is the expected place of the technology in current practice?

This is a new drug which is thought to be of use in patients with Gastro-intestinal tumours similar to another called Imatinib. There have been some trials on the latter's use recently though the results are awaited. These drugs can either be used to treat advanced disease, recurrent disease, or residual disease after surgery. They may also be used to downsize the tumour before resection and possibly as an adjuvant to surgical resection in higher risk tumours.

There are currently Guidelines for the management of GISTs put together by a multidisciplinary group and published by Novartis Oncology in February 2008

I am only aware of the results of Imatinib (Glivec) and cannot comment on the results/complications/side effect of Sunitinib. An Oncologist would be best placed to look into this part of the review.

The advantages and disadvantages of the technology

See above

Any additional sources of evidence

I am not aware of any specific evidence relating to Sunitinib, see above.

Implementation issues

This will relate to cost and efficacy which are both as yet unknown

04.11.08

